Abstract:Objectives: To prospectively compare the effects on heart rate (HR) and contrast enhancement efficacy of iopamidol-370 and iodixanol-320 in contrast-enhanced, multidetector-row computed tomography (CE-MDCT).Methods: IMPACT is a multicenter, double-blind study involving 166 patients undergoing CE-MDCT of the liver (n = 121) or peripheral arteries (n = 45) randomized to receive equi-iodine doses (40 gI) of iopamidol-370 or iodixanol-320 intravenous at 4 mL/s. CE-MDCT was performed using 16-MDCT scanners according to predefined imaging protocols. HR was measured with the patient in the supine position before and continuously for 5 minutes after contrast medium administration. Mean and peak increases in HR and the proportion of subjects with predefined HR increases (>5 to <10, 10 to <15, 15 to <20, >20 bpm) were compared in the 2 populations. Liver images were assessed by 2 independent, blinded readers for contrast enhancement [Hounsfield unit (HU)], using predefined regions-of-interest during the arterial and portal-venous phase of enhancement.Results: Effects on HR: Eighty-four subjects received iopamidol-370 whereas 82 received iodixanol-320. Mean age, gender distribution, weight, total iodine dose, dose/body weight, concomitant medications and use of beta-blockers were comparable in the 2 groups. Mean baseline HR was similar in the 2 groups (iopamidol-370: 72.3 +/- 12.5 bpm; iodixanol-320: 74.5 +/- 11.9 bpm). Mean changes from baseline to peak postdose were similar in the 2 groups (8.0 +/- 9.3 bpm after iopamidol-370 and 8.4 +/- 14.7 after iodixanol-320, P = 0.72). The proportion of subjects in each group having increases of <5, >5 to <10, 10 to <15, 15 to <20, or >20 bpm was comparable (P = 0.87). Two subjects experienced postcontrast tachycardia (HR increase >70 bpm, peak HR of 146 and 164 bpm), both in the iodixanol-320 group (2.4%). Contrast Enhancement: Of the 121 patients undergoing liver CT, 60 received iopamidol-370 whereas 61 received iodixanol-320. Mean age, gender distribution, weight, total iodine dose, and dose/body weight were comparable in the 2 groups. Iopamidol-370 provided significantly higher HU values in abdominal aorta during the arterial phase of enhancement for both readers [R1: 301.3 +/- 80.2 vs. 273.6 +/- 65.9 HU, 95% confidence interval (6.1 - 56.8), P = 0.02; R2: 302.0 +/- 73.6 vs. 275.1 +/- 62.9 HU, 95% confidence interval (2.3 - 51.3), P = 0.03]. No significant difference was observed between the 2 contrast medium during the portal venous phase of enhancement.Conclusions: When the same injection rate and iodine dose is used, the effects on HR of bolus intravenous injections of iopamidol-370 and iodixanol-320 were similar. Iopamidol-370 provides significantly greater enhancement during the arterial phase and similar enhancement during the portal venous phase compared with iodixanol-320.

Effect of iodinated contrast media on peripheral blood mononuclear cells in terms of cell viability, cell cycle and oxidative stress in an in vitro system

In vitro investigation the effects of iodinated contrast media on endothelial cell viability, cell cycle, and apoptosis

The effects of non-ionic contrast medium on the hemorheology in vitro and in vivo.

Toxic Effects of a High Dose of Non-Ionic Iodinated Contrast Media on Renal Glomerular and Aortic Endothelial Cells in Aged Rats in Vivo.

Comparative Safety Profiles and Usage Patterns of Iodinated Contrast Media in Medical Imaging

Thyroid Dysfunction Risk After Iodinated Contrast Media Administration: A Prospective Longitudinal Cohort Analysis

Universal Use of Nonionic Iodinated Contrast Medium for CT: Evaluation of Safety in a Large Urban Teaching Hospital

Adverse skin reactions to iodinated x-ray contrast agents in healthy rats

Retrospective Analysis of Acute Adverse Reactions of 4 Iodine Contrast Agents

Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial

Extracting 3D Angiography Data from Simulated Computed Tomography Angiography Scans Using Low Iodine Contrast Agent

Frequently Asked Questions: Iodinated Contrast Agents

Retrospective analysis of non-laboratory-based adverse drug reactions induced by intravenous radiocontrast agents in a Joint Commission International-accredited academic medical center hospital in China

Prevention and Management of Adverse Reactions Induced by Iodinated Contrast Media

Renal Tolerability of Iopromide and Iodixanol in 562 Renally Impaired Patients Undergoing Cardiac Catheterisation: the Direct Study

A Comparison of the Efficacy and Safety of Iopamidol-370 and Iodixanol-320 in Patients Undergoing Multidetector-Row Computed Tomography.

Evaluation of the acute adverse reaction of contrast medium with high and moderate iodine concentration in patients undergoing computed tomography

Feasibility of low dose Iso-osmolar Contrast Media in 640-slice Volume CT Coronary Angiography

A Comparison of the Efficacy and Safety of Iopamidol-370 and Iodixanol-320 in Patients Undergoing Multidetector-Row Computed Tomography

Iodinated Contrast Administration and Risks of Thyroid Dysfunction: A Retrospective Cohort Analysis of the U.S. Veterans Health Administration System

A comparison of the use of contrast media with different iodine concentrations for enhanced computed tomography